lapatinib + gemcitabine

**Lapatinib + gemcitabine** is an investigational combination therapy evaluated primarily for HER2-overexpressing cancers such as breast cancer and cholangiocarcinoma. Lapatinib is an oral small molecule inhibitor targeting the tyrosine kinase domains of both HER2 (ERBB2) and EGFR (HER1), blocking downstream signaling and limiting tumor cell proliferation and survival. Gemcitabine is a nucleoside analog (antimetabolite) chemotherapeutic agent that is incorporated into DNA, thereby inhibiting DNA synthesis and triggering apoptosis in rapidly dividing cells. The combination exerts synergistic anti-tumor activity: lapatinib simultaneously inhibits HER2 signaling and ABCB1 transporters, leading to reduced drug efflux and enhanced intracellular accumulation of the active gemcitabine metabolite, thereby overcoming resistance mechanisms commonly limiting gemcitabine efficacy. This dual mechanism provides a strong preclinical rationale for the combination's further clinical evaluation, particularly in HER2-overexpressed cholangiocarcinoma and advanced breast cancer[1][2].

Brand names

TykerbTyverb

Other names

lapatinib and gemcitabine combinationlapatinib-gemcitabine